Fexagratinib
As of the edition of 20 October 2026, Fexagratinib is a small molecule: in active development; acts on FGFR1, FGFR2 and FGFR3 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2015
- Kind
- Small molecule
- Registered trials
- 19, 2 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Lungs and airways; Blood and lymph; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Fexagratinib.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 4 | 2 | 1 | 1 |
| Phase 2 | 13 | 7 | 2 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 19 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 2009 to now |
| Abbisko Therapeutics | Lead sponsor of trials | 2020 to now |